Xin Lu received her Bachelor’s degree in Clinical Medicine from Hebei Medical University in 1986, her Master’s degree in Obstetrics and Gynecology from Hebei Medical University in 1994, and her Ph.D. in Gynecologic Oncology from Shinshu University School of Medicine, Japan, in 1999. She conducted postdoctoral research and academic visits at the University of Kentucky and the University of California, San Francisco. Since 2002, she has worked at the Obstetrics and Gynecology Hospital of Fudan University, where she is currently a Chief Physician and doctoral supervisor. Her research mainly focuses on gynecologic oncology, epithelial ovarian cancer, tumor invasion and metastasis, angiogenesis, tumor microenvironment, and molecular mechanisms related to ovarian cancer progression. Representative publications: 1. Bai Y, Li L, Li J, Lu X. Association analysis of FXYD5 with prognosis and immunological characteristics across pan-cancer. Heliyon. 2024;10:e30727. doi:10.1016/j.heliyon.2024.e30727. 2. Xu H, Li W, Yue H, Bai Y, Li J, Lu X, Wang J. S100B induces angiogenesis via the clathrin/FOXO1/beta-catenin signaling pathway and contributes to Bevacizumab resistance in epithelial ovarian cancer. Journal of Advanced Research. 2025. doi:10.1016/j.jare.2025.05.060. 3. Bai Y, Li LD, Li J, Chen RF, Yu HL, Sun HF, Wang JY, Lu X. A FXYD5/TGFbeta/SMAD positive feedback loop drives epithelial-to-mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. International J